Today's Daily Dose brings you news about Array's encouraging results from phase III melanoma study; AstraZeneca's newfound hope in Imfinzi in lung cancer setting; Blueprint's ongoing phase I trial of BLU-554 in advanced hepatocellular carcinoma; Bristol-Myers' CheckMate -238 trial and Immune Design's soft tissue sarcoma trial results.
from RTT - Biotech http://ift.tt/2fcEwOW
via IFTTT
No comments:
Post a Comment